Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Haller

Showing results (261-270 of 395) with videos related to

Pageof 40
Sort By:
Human Molecular Genetics|June 2, 2009
Mitochondrial abnormalities, energy deficit and oxidative stress are features of calpain 3 deficiency in skeletal muscleIrina Kramerova, Elena Kudryashova, Benjamin Wu, et al.
International Journal of Radiation Oncology, Biology, Physics|August 30, 2008
Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297David I Rosenthal, Paul J Catalano, Daniel G Haller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2003
Impact of diabetes mellitus on outcomes in patients with colon cancerJeffrey A Meyerhardt, Paul J Catalano, Daniel G Haller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancerM J O'Connell, J A Mailliard, M J Kahn, et al.
Gastrointestinal Cancer Research : GCR|March 6, 2009
Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal OncologyJohn L Marshall, Daniel G Haller, Aimery de Gramont, et al.
The New England Journal of Medicine|April 20, 2001
Molecular predictors of survival after adjuvant chemotherapy for colon cancerT Watanabe, T T Wu, P J Catalano, et al.
Human Molecular Genetics|December 24, 2016
Use of antisense oligonucleotides to correct the splicing error in ISCU myopathy patient cell linesGregory P Holmes-Hampton, Daniel R Crooks, Ronald G Haller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089Daniel G Haller, Paul J Catalano, John S Macdonald, et al.
Cancer|July 25, 2003
Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinomaJeffrey A Meyerhardt, Paul J Catalano, Daniel G Haller, et al.
Annals of Internal Medicine|July 4, 1998
Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology GroupR M Goldberg, T R Fleming, C M Tangen, et al.
Pageof 40

Showing results (261-270 of 395) with videos related to

Sort By:
Pageof 40
Human Molecular Genetics|June 2, 2009
Mitochondrial abnormalities, energy deficit and oxidative stress are features of calpain 3 deficiency in skeletal muscleIrina Kramerova, Elena Kudryashova, Benjamin Wu, et al.
International Journal of Radiation Oncology, Biology, Physics|August 30, 2008
Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297David I Rosenthal, Paul J Catalano, Daniel G Haller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2003
Impact of diabetes mellitus on outcomes in patients with colon cancerJeffrey A Meyerhardt, Paul J Catalano, Daniel G Haller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancerM J O'Connell, J A Mailliard, M J Kahn, et al.
Gastrointestinal Cancer Research : GCR|March 6, 2009
Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal OncologyJohn L Marshall, Daniel G Haller, Aimery de Gramont, et al.
The New England Journal of Medicine|April 20, 2001
Molecular predictors of survival after adjuvant chemotherapy for colon cancerT Watanabe, T T Wu, P J Catalano, et al.
Human Molecular Genetics|December 24, 2016
Use of antisense oligonucleotides to correct the splicing error in ISCU myopathy patient cell linesGregory P Holmes-Hampton, Daniel R Crooks, Ronald G Haller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089Daniel G Haller, Paul J Catalano, John S Macdonald, et al.
Cancer|July 25, 2003
Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinomaJeffrey A Meyerhardt, Paul J Catalano, Daniel G Haller, et al.
Annals of Internal Medicine|July 4, 1998
Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology GroupR M Goldberg, T R Fleming, C M Tangen, et al.
Pageof 40